EXCLUSIVITY OF OPTION. This Option to Purchase Agreement is exclusive and non-assignable and exists solely for the benefit of the named parties above. Should Buyer/Tenant attempt to assign, convey, delegate, or transfer this option to purchase without the Seller/Landlord’s express written permission, any such attempt shall be deemed null and void.
EXCLUSIVITY OF OPTION. This Addendum is exclusive, non-transferrable and non- assignable. The powers contained in this Addendum shall exist exclusively for the Tenant and shall not be conveyed, transferred, or delegated to any such third (3rd) party. In the event of death of the Tenant, this Addendum shall be considered null and void with no rights for any heirs of the Tenant’s estate.
EXCLUSIVITY OF OPTION. The Option to Purchase is exclusive and non-assignable and exists solely for the benefit of Tenant. Should Tenant attempt to assign, convey, delegate, or transfer the Option to Purchase without Landlord’s express written permission, any such attempt shall be deemed null and void, and the Option to Purchase may voided at Landlord’s discretion, which shall subject all credits otherwise due to Tenant at the Closing to be forfeited by Xxxxxx.
EXCLUSIVITY OF OPTION. This option to purchase is exclusive and non- assignable. Any attempted assignment, delegation, transfer or conveyance of this option to purchase without the Seller/Landlord’s express written permission is void.
EXCLUSIVITY OF OPTION. This Agreement is exclusive and non-assignable and exists solely for the benefit of the named parties above. Should Optionee attempt to assign, convey, delegate, or transfer this option to lease without the Optionor’s express written permission, any such attempt shall be deemed null and void.
EXCLUSIVITY OF OPTION. This Option Addendum and the Option are exclusive and non-assignable and exist solely for the benefit of the Buyer. Should Buyer attempt to assign, convey, delegate, or transfer the Option without Seller's express written consent, the Option shall be deemed null and void. Notwithstanding the foregoing, this Option Addendum and the Option shall be binding on, and shall inure to the benefit of each parties' respective heirs.
EXCLUSIVITY OF OPTION. This Option to Purchase is exclusive for the Tenant listed above. This option may not be assigned, conveyed, transferred, or delegated without the Landlord’s explicit written permission. Any attempt to do so without the Landlord’s written permission is a violation of this Agreement.
EXCLUSIVITY OF OPTION. (A) This Option to Purchase is exclusive and non-assignable and exists solely for the benefit of the Tenant or its permitted assignees as specified in Section 11 of the Lease. (B) Provided Landlord has delivered to Tenant written notice of any offer to purchase as described in Section 27 above, this Option to Purchase shall become null and void in the event the Landlord has transferred title of the Leased Premises to an unrelated third party and Tenant elected to not exercise its Right of First Refusal in the Lease.
EXCLUSIVITY OF OPTION. Affymax and Glaxo agree that they shall not offer to any third party the opportunity to obtain a license with respect to Related Technology or enter into any license with any third party with respect to Related Technology, until the first to occur of expiration of the period commencing upon MDC's receipt of notice and relevant data and information pursuant to Section 5.2(a), and ending sixty (60) days thereafter, if MDC does not during such period notify Affymax of MDC's interest in obtaining a license with respect to such Related Technology, (ii) the date upon which MDC notifies Affymax that MDC is not interested in obtaining such license, or (iii) the expiration of the Negotiation Period, if the Parties have not entered into a license with respect to such Related Technology prior to such time. After such date, Affymax and Glaxo shall be free to offer to third parties the opportunity to obtain a license, and to enter into a license with respect to such Related Technology on terms at least as favorable to Affymax or Glaxo as those last offered by MDC.
EXCLUSIVITY OF OPTION. During the period commencing on the Effective Date and ending on the expiration of the Option Period, AVEO will (a) neither offer nor grant a license or other rights to any Third Party that would preclude AVEO from being able to grant the rights and licenses to Ophthotech that are contemplated in Exhibit C, or discuss or negotiate with any Third Party any potential or proposed transaction that, if entered into, would prevent AVEO from being able to grant the rights and licenses to Ophthotech that are contemplated in Exhibit C, and (b) not engage in any research, development or commercialization of the Compound in the Field, other than as may be requested by Ophthotech to support Ophthotech’s conduct of Option Period Research.
